Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer

Maha Hussain; Karim Fizazi; Fred Saad; Per Rathenborg; Neal D. Shore; Ubirajara Ferreira; Petro Ivashchenko; Eren Demirhan; Katharina Modelska; De Phung; Andrew Krivoshik; Cora N. Sternberg

doi:10.1056/nejmoa1800536

Abstract

Among men with nonmetastatic, castration-resistant prostate cancer with a rapidly rising PSA level, enzalutamide treatment led to a clinically meaningful and significant 71% lower risk of metastasis or death than placebo. Adverse events were consistent with the established safety profile of enzalutamide. (Funded by Pfizer and Astellas Pharma; PROSPER ClinicalTrials.gov number, NCT02003924 .).

Keywords

EnzalutamideProstate cancerMedicineOncologyCastrationInternal medicineCancerUrologyAndrogen receptorHormone

Affiliated Institutions

Related Publications

Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer

Ian D. Davis , Andrew Martin , Martin R. Stockler +29 more

Enzalutamide was associated with significantly longer progression-free and overall survival than standard care in men with metastatic, hormone-sensitive prostate cancer receivin...

2019 New England Journal of Medicine 1481 citations

Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer

Kim N. , Neeraj Agarwal , Anders Bjartell +17 more

In this trial involving patients with metastatic, castration-sensitive prostate cancer, overall survival and radiographic progression-free survival were significantly longer wit...

2019 New England Journal of Medicine 1384 citations

Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer

Matthew R. Smith , Fred Saad , Simon Chowdhury +15 more

Among men with nonmetastatic castration-resistant prostate cancer, metastasis-free survival and time to symptomatic progression were significantly longer with apalutamide than w...

2018 New England Journal of Medicine 1271 citations

Olaparib for Metastatic Castration-Resistant Prostate Cancer

Johann S. de Bono , Joaquı́n Mateo , Karim Fizazi +17 more

In men with metastatic castration-resistant prostate cancer who had disease progression while receiving enzalutamide or abiraterone and who had alterations in genes with a role ...

2020 New England Journal of Medicine 2067 citations

Genomic correlates of clinical outcome in advanced prostate cancer

Wassim Abida , Joanna Cyrta , Glenn Heller +40 more

Heterogeneity in the genomic landscape of metastatic prostate cancer has become apparent through several comprehensive profiling efforts, but little is known about the impact of...

2019 Proceedings of the National Academy o... 1301 citations

Publication Info

Year: 2018
Type: article
Volume: 378
Issue: 26
Pages: 2465-2474
Citations: 1003
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1003

OpenAlex

Cite This

APA Style

                            
                                
                                    Maha Hussain, 
                                
                                    Karim Fizazi, 
                                
                                    Fred Saad
                                
                                et al.
                            
                            (2018). 
                            Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer. 
                            New England Journal of Medicine
                            , 378
                            (26)
                            , 2465-2474.
                            https://doi.org/10.1056/nejmoa1800536
                        

Identifiers

DOI: 10.1056/nejmoa1800536